Related Experiment Video
Updated: May 26, 2026
07:00
Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
GLP-1 based therapies: differential effects on fasting and postprandial glucose
M S Fineman1, B B Cirincione, D Maggs
1Elcelyx Therapeutics, Inc., San Diego, CA, USA. marksfineman@gmail.com
Diabetes, Obesity & Metabolism
|January 12, 2012
Summary
Glucagon-like peptide-1 (GLP-1) therapies, including DPP-4 inhibitors and GLP-1 receptor agonists, offer effective type 2 diabetes management. Tailoring treatment to individual patient needs optimizes glucose control and weight management.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Glucagon-like peptide-1 (GLP-1) is a key hormone regulating glucose and weight.
- Its therapeutic potential for type 2 diabetes is limited by rapid degradation by dipeptidyl peptidase-4 (DPP-4).
- Current therapies include DPP-4 inhibitors and GLP-1 receptor (GLP-1R) agonists.
Purpose of the Study:
- To review and compare DPP-4 inhibitors, short-acting GLP-1R agonists, and long-acting GLP-1R agonists.
- To highlight their distinct mechanisms and effects on glucose control.
- To propose personalized treatment strategies for type 2 diabetes.
Main Methods:
- Comparative review of existing literature on GLP-1 mediated therapies.
- Analysis of pharmacokinetic and pharmacodynamic differences.
- Discussion of clinical implications for type 2 diabetes management.
Main Results:
- DPP-4 inhibitors reduce GLP-1 degradation.
- GLP-1R agonists offer varying durations of action with distinct impacts on fasting and postprandial glucose.
- All therapeutic classes are valuable tools in type 2 diabetes management.
Conclusions:
- The choice of GLP-1 mediated therapy should be individualized based on patient requirements.
- These therapies offer advantages over insulin, including lower hypoglycemia risk and weight gain.
- Optimized use of GLP-1 therapies may represent a paradigm shift in type 2 diabetes treatment.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...